Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

506
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
506
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

430
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
430
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

628
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
628
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

392
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
392
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

417
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
417

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The PROMISE-ACHD Score: Prediction of Perioperative Mortality and Major Morbidity in Adult Congenital Heart Disease.

JACC. Advances·2026
Same author

Aortic valve neocuspidization for a low-birth-weight neonate with severe aortic stenosis with regurgitation.

JTCVS techniques·2026
Same author

Dislodgement of a subcutaneous shock lead owing to loop release in the device pocket in a pediatric patient with congenital long QT syndrome.

HeartRhythm case reports·2026
Same author

Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Reflects Global Pathophysiology and Predicts All-Cause Morbidity and Mortality in Patients With Fontan Circulation.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Ethics of the Design of Animal-like Robots.

Science and engineering ethics·2026
Same author

Comparative Long-Term Outcomes of Anatomical and Physiological Repair for Corrected Transposition.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026

Related Experiment Video

Updated: Feb 22, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Cardiac Resynchronization Therapy for Failing Single Ventricle Physiology.

Yuji Tominaga1, Heima Sakaguchi2, Masashi Takeshita1

  • 1Department of Pediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Centre, Osaka, 565-8565, Japan.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|February 20, 2026
PubMed
Summary

Cardiac resynchronization therapy improved heart function and heart failure symptoms in single ventricle patients with dyssynchrony. This therapy shows promise for improving outcomes in this complex patient group.

Keywords:
cardiac resynchronization therapyheart failureventricular dyssynchrony

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.0K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.0K

Related Experiment Videos

Last Updated: Feb 22, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.0K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.0K

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Congenital Heart Disease

Background:

  • Single ventricle physiology presents unique challenges in managing heart failure and ventricular dyssynchrony.
  • Ventricular dyssynchrony contributes to poor outcomes in single ventricle patients, exacerbating heart failure symptoms.

Purpose of the Study:

  • To evaluate the mid-term efficacy of cardiac resynchronization therapy (CRT) in patients with single ventricle physiology, heart failure, and ventricular dyssynchrony.
  • To assess the impact of CRT on hemodynamic parameters, functional status, and long-term survival in this cohort.

Main Methods:

  • Retrospective review of single ventricle patients undergoing CRT between 2010 and 2024.
  • Dyssynchrony defined by QRS duration (≥130 ms) and mechanical assessment; CRT indications based on hemodynamic improvement.
  • Patients categorized into Group G (post-bidirectional Glenn) and Group F (post-Fontan completion); analysis included survival, functional class, and organ function.

Main Results:

  • CRT improved systemic ventricular ejection fraction (Group G: 30-40%, Group F: 30-53%) and cardiac index one year post-procedure.
  • Five-year survival rates were high (89% in Group G, 82% in Group F); Fontan completion rate was 76% at 5 years in Group G.
  • Group F showed improved brain natriuretic peptide levels, stable hepatic function, and no reported protein-losing enteropathy.

Conclusions:

  • Cardiac resynchronization therapy effectively enhances systemic ventricular function and alleviates heart failure symptoms in single ventricle patients.
  • CRT represents a potentially valuable therapeutic strategy for single ventricle patients experiencing heart failure and ventricular dyssynchrony, improving their quality of life and prognosis.